Brief: Jacobio Pharmaceuticals Says Submission Of New Drug Application
06/05/2024 15:39
May 6 (Reuters) - Jacobio Pharmaceuticals 1167.HK :
* SUBMISSION OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR
GLECIRASIB
* NEW DRUG APPLICATION FOR DEVELOPED KRAS G12C INHIBITOR
GLECIRASIB SUBMITTED TO CENTER FOR DRUG EVALUATION OF NMPA
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan